gut microbiota
Targeting E. lenta or boosting neutrophil function may lead to new treatment strategies for bronchiectasis and related lung diseases.
Nutrient competition is the main mechanism of C. difficile inhibition, hinting at the potential for targeted therapies with probiotics instead of traditional FMT.
Researchers have developed new tools to better understand the role of Bifidobacterium breve, revealing its competitive growth strategies and potential for supporting the immune system.
Delayed microbiota maturation in infants with cystic fibrosis could contribute to disease complications, highlighting potential therapeutic targets.
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
Phages could be used as a drug delivery system for conditions such as inflammation and obesity.
Microbiota analysis could help sexual assault investigations by detecting microbial markers of contact, even in cases where traditional DNA evidence is lacking.
L-ornithine can be an additional therapy to boost the efficacy of ustekinumab in people with Crohn’s disease.
This pioneering three-in-one formula uniquely combines pasteurized Akkermansia muciniphila AKK PROBIO, DigeSEB® broad-spectrum digestive enzymes, and B-Complex vitamins.
Reproducible biomarkers produced by several bacteria show potential as a non-invasive tool for IBD diagnosis, discriminating ulcerative colitis and Crohn’s disease patients from healthy individuals.
